FDA ACTIONS
The labels of 2 formulations of finasteride, used to treat enlarged prostate and male-pattern baldness, are being revised to indicate that additional sexual side effects may persist after the drug has been discontinued, FDA announced. » More |
CONTINUING EDUCATION
E-prescribing, a paperless, real-time transmission of data, places pharmacists squarely within the healthcare technology team.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
CLINICAL NEWS
Doctors debate whether men with elevated cholesterol levels who are otherwise healthy should still take statins, in a new series in JAMA, Dueling Viewpoints. » More |
|
Teenagers with high levels of uric acid have an increased risk for high blood pressure, according to a new study published in the April 2012 issue of the journal Hypertension.
» More |
|
Current use of warfarin as a stroke prevention therapy in patients with nonvalvular atrial fibrillation is associated with a lower rate of residual stroke or systemic embolism compared with previous data, according to a recent study. » More |
|
A set of 11 evidence-based recommendations for managing pain with pharmacotherapy in patients suffering inflammatory arthritis were reported by an international panel online March 24 in Rheumatology. » More |
|
The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis, according to a clinical trial that appeared in the JAMA’s Archives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered. » More |
|
Phthalate metabolites, chemicals commonly used in plastics, cosmetics, and pharmaceuticals, were linked to an increased risk for the development of type 2 diabetes in the elderly, a recent study found. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
